Skip to main content

Featured

Trump's 50% Auto Tariff Threat: What It Means If You're Buying a Car in 2027

  Vehicle prices in Canada are already up thousands of dollars since the trade war began. A threatened doubling of auto tariffs on January 1, 2027 could push them higher still — here's what's confirmed, what's not, and what it means if you're in the market for a car. On Monday, U.S. President Donald Trump posted on Truth Social that tariffs on all Canadian-made cars, trucks, auto parts, and steel would rise to 50% starting January 1, 2027 — effectively doubling the current 25% rate. The threat landed hours after cross-border trade talks collapsed late Friday night, triggering a separate round of 50% tariffs on roughly $20 billion of other Canadian goods and a promised Canadian retaliation package set for September 8. For anyone shopping for a new or used vehicle in Ontario — or watching an auto-sector paycheque — here's what's actually changed, and what's still just a threat. What Trump actually announced The post is specific on rate and date but light on me...
Post a Comment
Read more

article

Labels

Quebec Declines Coverage for Newly Approved Alzheimer’s Treatment

 

Quebec has announced that it will not cover the cost of lecanemab (Leqembi®), the first disease-modifying Alzheimer’s drug recently approved by Health Canada. The medication, conditionally approved in late October 2025, is designed to slow the progression of early-stage Alzheimer’s disease by targeting amyloid plaques in the brain.

Health Canada’s approval was hailed as a breakthrough, offering hope to patients and families grappling with the devastating effects of dementia. Lecanemab has shown the ability to reduce cognitive decline by about 27% over 18 months in clinical trials. Despite this, Quebec’s public drug insurance plan, administered by the Régie de l’assurance maladie du Québec (RAMQ), has confirmed that the treatment will not be added to its list of covered medications.

The decision raises concerns about accessibility and affordability, as the drug is expected to be costly. While other provinces may still evaluate whether to include lecanemab in their formularies, Quebec’s refusal highlights ongoing debates about the balance between innovation, cost-effectiveness, and equitable access to care.

Advocates, including the Alzheimer Society of Canada, argue that denying coverage could leave many patients without access to a therapy that represents the first real step toward slowing the disease’s progression. Families and healthcare professionals are now calling for further discussions on how Canada’s healthcare system can adapt to emerging treatments that may reshape the future of dementia care.


Labels:

Comments

Post a Comment